Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean fever

Basit Öğe Kaydı
dc.authorid0000-0001-5902-8831en_US
dc.contributor.authorÇetin, Pınar
dc.contributor.authorSarı, İsmail
dc.contributor.authorSözeri, Betül
dc.contributor.authorCam, Özlem
dc.contributor.authorBirlik, Merih
dc.contributor.authorAkkoç, Nurullah
dc.contributor.authorÖnen, Fatoş
dc.contributor.authorAkar, Servet
dc.date.accessioned2024-07-12T21:04:07Z
dc.date.available2024-07-12T21:04:07Z
dc.date.issued2014en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstract—Herein, we reported our experience in colchicine-resistant familial Mediterranean fever (FMF) patients who are treated with anti-interleukin-1 (IL-1) drugs. A retrospective review of medical records of anti-IL-1 recipients was performed. The main clinical characteristics of these patients and the evolution after anti-IL-1 were recorded. There were 20 patients (11 male [M] and 9 female [F]). Despite regular colchicine treatment, median number of attacks per month and per year was 1 (1–4) and 12 (4– 50), respectively. Twelve patients were receiving anakinra, and eight patients were treated with canakinumab. The number of monthly and yearly attacks after IL-1 treatment was significantly decreased after the biologic agent (p<0.05). One patient did not respond to the treatment, and one patient developed serious infection during anti-IL-1. We also observed a significant decrease in proteinuria in the amyloidosis complicated FMF patients. Anti-IL-1 targeting drugs seem safe and effective therapies in colchicine-resistant FMF.en_US
dc.identifier.citationÇetin, P., Sarı, İ., Sözeri, B., Cam, Ö. vd. (2014). Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean fever. Inflammation, Springerlink. 38, s. 27-31.en_US
dc.identifier.endpage31en_US
dc.identifier.issn1573-2576
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage27en_US
dc.identifier.urihttps://link.springer.com/article/10.1007/s10753-014-0004-1
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3756
dc.identifier.volume38en_US
dc.institutionauthorCam, Özlem
dc.language.isoenen_US
dc.publisherSpringerlinken_US
dc.relation.ispartofInflammationen_US
dc.relation.isversionof10.1007/s10753-014-0004-1en_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKY01257
dc.subjectfamilial Mediterranean feveren_US
dc.subjectcolchicineen_US
dc.subjectanakinraen_US
dc.subjectcanakinumaben_US
dc.subjectrilonacepten_US
dc.subjectinterleukin-1 receptor antagonist proteinen_US
dc.subjectamyloidosisen_US
dc.titleEfficacy of interleukin-1 targeting treatments in patients with familial mediterranean feveren_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu